Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Obesity
Fierce Healthcare
Hims & Hers stock drops 30% after Novo Nordisk terminates deal
Hims & Hers stock plunged 30% on Monday after Novo Nordisk abruptly ended a collaboration to offer direct access to its weight loss drug Wegovy.
Heather Landi
Jun 23, 2025 12:00pm
Lilly fills out lineup of Zepbound doses on self-pay website
Jun 16, 2025 11:48am
PD-1 bispecifics, Enhertu, Regeneron-Hansoh—Fierce Pharma Asia
Jun 6, 2025 7:15am
Novo Nordisk signs on to support ADA’s obesity advocacy division
Jun 4, 2025 12:36pm
Roche lays plans for $700M next-gen obesity drug plant in NC
May 12, 2025 10:33am
Novo's Wegovy secures preferred obesity spot on CVS formulary
May 1, 2025 2:39pm
